| Autor: |
Eyre TA; Department of Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford. toby.eyre@ouh.nhs.uk., Barrington SF; King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London., Okosun J; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London., Abamba C; BSBMTCT data registry, 5th Floor Tabard House, Talbot Yard, Guy's Hospital, Great Maze Pond, London., Pearce RM; BSBMTCT data registry, 5th Floor Tabard House, Talbot Yard, Guy's Hospital, Great Maze Pond, London., Lee J; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London., Carpenter B; Department of Haematology, University College London Hospitals 235 Euston Road, London., Crawley CR; Department of Haematology and Bone Marrow Transplantation, Addenbrookes Hospital, Cambridge., Bloor AJC; Department of Haematology, The Christie Hospital NHS Trust, Manchester., Gilleece M; Department of Haematology and Bone Marrow Transplantation, Leeds Teaching Hospitals NHS Trust, Leeds., Nicholson E; Department of Haematology and Bone Marrow Transplantation, Royal Marsden Hospital, London., Shah N; Department of Haematology, Norfolk and Norwich University Hospitals, Norwich., Orchard K; Department of Haematology and Bone Marrow Transplantation, Southampton University Hospitals, Southampton., Malladi R; Department of Haematology and Bone Marrow Transplantation, Addenbrookes Hospital, Cambridge., Townsend WM; Department of Haematology, University College London Hospitals 235 Euston Road, London. |
| Abstrakt: |
The optimum management approach for patients with relapsed or refractory follicular lymphoma remains uncertain. Autologous stem cell transplantation (autoSCT) is considered a standard option in suitable, younger patients with relapsed follicular lymphoma. AutoSCT is associated with very durable remissions in a minority of subjects, but also with significant, well-established toxicities. Although positron emission tomography (PET) status prior to autoSCT is an established prognostic factor in diffuse large B-cell lymphoma and Hodgkin lymphoma, no data exist in follicular lymphoma. We describe survival outcomes according to pre-transplant PET status, classified by the Lugano criteria into complete metabolic remission (CMR) versus non-CMR, in 172 patients with relapsed or refractory follicular lymphoma within a national, multicenter, retrospective British Society of Blood and Marrow Transplantation and Cellular Therapy registry study. The median number of lines of therapy prior to SCT was three (range, 1-6). The median follow-up after SCT was 27 months (range, 3-70). The median progression-free survival for all patients after autoSCT was 28 months (interquartile range, 23- 36). There was no interaction between age at transplantation, sex, number of months since last relapse, Karnofsky performance status or comorbidity index and achieving CMR prior to autoSCT. Superior progression-free survival was observed in 115 (67%) patients obtaining CMR versus 57 (33%) non-CMR patients (3-year progression-free survival 50% vs. 22%, P=0.011) and by pre-SCT Deauville score (continuous variable 1-5, hazard ratio [HR]=1.32, P=0.049). PET status was independently associated with progression-free status (non-CMR HR=2.02, P=0.003), overall survival (non-CMR HR=3.08, P=0.010) and risk of relapse (non-CMR HR=1.64, P=0.046) after autoSCT by multivariable analysis. Our data suggest that pre- SCT PET status is of clear prognostic value and may help to improve the selection of patients for autoSCT. |
